Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Provided By GlobeNewswire
Last update: Oct 24, 2024
Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial
Read more at globenewswire.comNASDAQ:ERAS (7/28/2025, 11:31:38 AM)
1.755
+0.01 (+0.86%)
Find more stocks in the Stock Screener
